Eudald Felip
Overview
Explore the profile of Eudald Felip including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
444
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Felip E, Pradenas E, Romeo M, Marfil S, Trinite B, Urrea V, et al.
Mol Oncol
. 2022 Dec;
17(4):686-694.
PMID: 36495129
Patients with solid tumors have been a risk group since the beginning of the SARS-CoV-2 pandemic due to more significant complications, hospitalizations or deaths. The immunosuppressive state of cancer treatments...
12.
Ezeonwumelu I, Garcia-Vidal E, Felip E, Puertas M, Oriol-Tordera B, Gutierrez-Chamorro L, et al.
Front Immunol
. 2022 Sep;
13:1001068.
PMID: 36131914
The persistence of latent HIV reservoirs allows for viral rebound upon antiretroviral therapy interruption, hindering effective HIV-1 cure. Emerging evidence suggests that modulation of innate immune stimulation could impact viral...
13.
Ferrando-Diez A, Felip E, Pous A, Bergamino Sirven M, Margeli M
Cancers (Basel)
. 2022 Jul;
14(14).
PMID: 35884366
Despite the improvement achieved by the introduction of HER2-targeted therapy, up to 25% of early human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) patients will relapse. Beyond trastuzumab,...
14.
Pons L, Hernandez-Leon L, Altaleb A, Ussene E, Iglesias R, Castillo A, et al.
Sci Rep
. 2022 May;
12(1):8176.
PMID: 35581229
Digital counting methods were developed to decrease the high intra- and inter-observer variability of immunohistochemical markers such as Ki67, with most presenting a good correlation coefficient (CC). Since Ki67 is...
15.
Cortellini A, Gennari A, Pommeret F, Patel G, Newsom-Davis T, Bertuzzi A, et al.
J Natl Cancer Inst
. 2022 Apr;
114(7):979-987.
PMID: 35417006
Background: Fifteen percent of patients with cancer experience symptomatic sequelae, which impair post-COVID-19 outcomes. In this study, we investigated whether a proinflammatory status is associated with the development of COVID-19...
16.
Felip E, Gutierrez-Chamorro L, Gomez M, Garcia-Vidal E, Romeo M, Moran T, et al.
Cancers (Basel)
. 2022 Feb;
14(3).
PMID: 35158911
SAMHD1 is a deoxynucleotide triphosphate (dNTP) triphosphohydrolase with important roles in the control of cell proliferation and apoptosis, either through the regulation of intracellular dNTPs levels or the modulation of...
17.
Sant M, Bernat-Peguera A, Felip E, Margeli M
Cancers (Basel)
. 2022 Jan;
14(2).
PMID: 35053474
Breast cancer is currently classified by immunohistochemistry. However, technological advances in the detection of circulating tumor DNA (ctDNA) have made new options available for diagnosis, classification, biological knowledge, and treatment...
18.
Pinato D, Patel M, Scotti L, Colomba E, Dolly S, Loizidou A, et al.
JAMA Oncol
. 2021 Nov;
8(1):114-122.
PMID: 34817562
Importance: Whether the severity and mortality of COVID-19 in patients with cancer have improved in terms of disease management and capacity is yet to be defined. Objective: To test whether...
19.
Garrigos L, Saura C, Martinez-Vila C, Zambelli A, Bower M, Pistilli B, et al.
Ther Adv Med Oncol
. 2021 Nov;
13:17588359211053416.
PMID: 34777582
Background: Cancer patients are at higher risk of COVID-19 complications and mortality than the rest of the population. Breast cancer patients seem to have better prognosis when infected by SARS-CoV-2...
20.
Pinato D, Tabernero J, Bower M, Scotti L, Patel M, Colomba E, et al.
Lancet Oncol
. 2021 Nov;
22(12):1669-1680.
PMID: 34741822
Background: The medium-term and long-term impact of COVID-19 in patients with cancer is not yet known. In this study, we aimed to describe the prevalence of COVID-19 sequelae and their...